Mode
Home
Research
Clinical Trials Drug Pipeline Weekly Digests
Reference
Conditions Medications
Community
Questions
Text Size
Log in / Sign up
Home › Medications › nirmatrelvir-ritonavir

nirmatrelvir-ritonavir

1 published article · Updated continuously

Clinical Trial Landscape

Clinical Trials of nirmatrelvir-ritonavir

6 trials tracked of nirmatrelvir-ritonavir.

6Trials tracked
0Phase 3 & 4
0Recruiting
0With published results
Phase distribution
Phase 1 2 Other / NA 4
  1. Phase 1 Relative Bioavailability Study of Nirmatrelvir/Ritonavir Oral Powder Relative to the Commercial Tablets and Estimation of the Effect of Food on Bioavailability of the Nirmatrelvir/Ritonavir Oral Powder in Healthy Participants. Completed
  2. Phase 1 Relative Bioavailability Study of Nirmatrelvir/Ritonavir 4 Different Fixed Dose Combination Tablets Relative to the Commercial Tablets in Healthy Participants Completed
  3. N/A A Study to Learn About the Use of Paxlovid in Patients With COVID-19 in the Kingdom of Bahrain. Completed
  4. N/A A Study of COVID-19 Patients Receiving Treatment With Nirmatrelvir; Ritonavir in the Kingdom of Saudi Arabia Completed
  5. N/A A US Study to Look at Loss of Work and Healthcare Costs for People Affected With Mild-to-moderate COVID 19 Who Have High Chances of the Disease Becoming Severe Completed
  6. N/A A Study to Learn About PAXLOVID (a Commercial Medicine) In People With COVID-19 Completed

Showing the 6 most-cited and recently-updated of 6 trials. Browse the full registry →

Trial data sourced from ClinicalTrials.gov. Counts describe the research landscape and are not a treatment recommendation. Informational only — not medical advice.

HCP Mode — summaries include clinical detail, trial data, and statistical outcomes.
Patient Mode — summaries use plain language, avoiding clinical jargon.
Nirmatrelvir-ritonavir reduced viral production by approximately 55% in SARS-CoV-2 BA.2-infected patients in Shanghai
Infectious Disease Cohort
Nirmatrelvir-ritonavir reduced viral production by approximately 55% in SARS-CoV-2 BA.2-infected patients in Shanghai Your COVID Pill May Work Better—Or Worse—Than You Think
This cohort study of 48,243 SARS-CoV-2 BA.2-infected patients in Shanghai evaluated nirmatrelvir-ritonavir exposure.
How well your Paxlovid works depends heavily on your age and vaccination status.
medRxiv Apr 13, 2026